Department of Biomedical Engineering, Tufts University, Medford, MA, USA.
J Cardiovasc Transl Res. 2011 Oct;4(5):575-91. doi: 10.1007/s12265-011-9303-1. Epub 2011 Aug 5.
Tissue-engineered cardiac constructs are a high potential therapy for treating myocardial infarction. These therapies have the ability to regenerate or recreate functional myocardium following the infarction, restoring some of the lost function of the heart and thereby preventing congestive heart failure. Three key factors to consider when developing engineered myocardial tissue include the cell source, the choice of scaffold, and the use of biomimetic culture conditions. This review details the various biomaterials and scaffold types that have been used to generate engineered myocardial tissues as well as a number of different methods used for the fabrication and culture of these constructs. Specific bioreactor design considerations for creating myocardial tissue equivalents in vitro, such as oxygen and nutrient delivery as well as physical stimulation, are also discussed. Lastly, a brief overview of some of the in vivo studies that have been conducted to date and their assessment of the functional benefit in repairing the injured heart with engineered myocardial tissue is provided.
组织工程心脏构建物是治疗心肌梗死的一种很有前途的治疗方法。这些疗法能够在梗死发生后再生或重新构建功能性心肌,恢复心脏的部分丧失功能,从而预防充血性心力衰竭。在开发工程化心肌组织时,需要考虑三个关键因素,包括细胞来源、支架选择和仿生培养条件。本文详细介绍了用于生成工程化心肌组织的各种生物材料和支架类型,以及用于制造和培养这些构建物的多种不同方法。还讨论了体外创建心肌组织等效物的特定生物反应器设计注意事项,例如氧气和营养物质的输送以及物理刺激。最后,简要介绍了迄今为止进行的一些体内研究及其对用工程化心肌组织修复受损心脏的功能益处的评估。